Vai al contenuto principale

Luca Tonella

Contatti

Supervisore

Franco Veglio

Attività di ricerca

Melanoma is one of the most aggressive skin cancers. The 5-year survival rate of stage III melanoma patients ranges from 93% (IIIA) to 32% (IIID) with a high risk of recurrence after complete surgery. The introduction of target and immune-therapies has dramatically improved the overall survival, but it remains crucial to identify patients with a high risk of relapse who will benefit from adjuvant therapy and to determine the best treatment choice. The project aims to identify novel biomarkers (prognostic and/or predictive), through the analysis by Next-Generation Sequencing of stage III/IV NED melanoma samples.
The first step of the project will be the characterization of primary melanoma tumour, using the Illumina TSO500 panel. The panel is able to evaluate more than 500 genes involved in tumorigenesis, immunity and microenvironment. Next, we will study liquid biopsies of patients treated in adjuvant therapy, with the aim to follow the disease over time and predict the risk of relapse/progression.

Arese V et al.

Autoimmune connective tissue diseases and pregnancy.

Ribero S et al.

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experience

   

Bossi P et al.

Are fusion transcripts in relapsed/metastatic head and neck cancer patients predictive of response to anti-EGFR therapies?

Quaglino P et al.

Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient

De Cecco, L et al.

Dissecting heterogeneity and molecular mechanisms involved in paranasal sinus cancer

   

Bossi P et al.

Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma

Quaglino P et al.

Correlation between CT scan findings at 3 and 6 months and pattern of response, progression-free survival and overall survival in advanced metastatic melanoma patients treated by anti-PD1 monotherapy: a single institution retrospective study

Tonella L et al.

Gene expression signatures for head and neck cancer patient stratification: are results ready for clinical application?

Quaglino P et al.

Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome

Quaglino P et al.

Metastatic melanoma treatment with checkpoint inhibitors in the COVID‐19 era: experience from an Italian skin cancer unit

Alfieri S et al.

Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma

Barreiro-Capurro A et al.

Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study

Quaglino P et al.

Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit

  • 2021_UNITO-POLITO CONFERENCE SERIES IN CANCER. NANOSCIENCE IN CANCER IMMUNOTHERAPY
  • December 2021_How to write a scientific paper
  • September 2023_Harvard medical school_Immuno-Oncology
  • Ultimo aggiornamento: 10/10/2023 22:41
    Location: https://dott-fisiopatologia.campusnet.unito.it/robots.html
    Non cliccare qui!